| Cash Flow | 2025-09-28 | 2025-06-29 | 2025-03-30 | 2024-09-29 |
|---|---|---|---|---|
| Net earnings | 21,688 | 16,536 | 10,999 | 10,635 |
| Depreciation and amortization of property and intangibles | 5,492 | 3,715 | 1,772 | 5,443 |
| Stock based compensation | 1,045 | 698 | 288 | 938 |
| Asset write-downs | 123 | 30 | 30 | 379 |
| Charges for acquired in-process research and development assets | 109 | 92 | 16 | 1,252 |
| (gain) on kenvue separation | - | - | - | 0 |
| Net gain on sale of assets/businesses | 131 | 74 | 75 | 225 |
| Deferred tax provision | 5,215 | 2,997 | 2,172 | -2,167 |
| Credit losses and accounts receivable allowances | -6 | 3 | -4 | -11 |
| Increase in accounts receivable | 2,172 | 2,283 | 926 | 1,259 |
| Increase in inventories | 1,404 | 656 | 146 | 1,038 |
| Increase in accounts payable and accrued liabilities | 1,111 | -886 | -2,126 | 2,713 |
| (increase)/decrease in other current and non-current assets | 7,653 | 6,194 | 1,317 | -949 |
| Decrease in other current and non-current liabilities | -6,196 | -5,926 | -6,509 | -326 |
| Net cash flows from operating activities | 17,221 | 8,052 | 4,174 | 17,283 |
| Additions to property, plant and equipment | 2,995 | 1,838 | 795 | 2,812 |
| Proceeds from the disposal of assets/businesses, net (note 10) | 408 | 332 | 279 | 623 |
| Acquisitions, net of cash acquired (note 10) | 14,459 | 14,458 | 0 | 15,145 |
| Acquired in-process research and development assets / related milestones (note 10) | 385 | 369 | 14 | 1,250 |
| Purchases of investments | 677 | 431 | 251 | 1,464 |
| Sales of investments | 1,442 | 953 | 218 | 2,172 |
| Credit support agreements activity, net | -2,338 | -2,684 | 296 | 699 |
| Other (including capitalized licenses and milestones) | 99 | 66 | 30 | 102 |
| Net cash used for investing activities | -19,103 | -18,561 | -297 | -17,279 |
| Dividends to shareholders | 9,250 | 6,118 | 2,989 | 8,839 |
| Repurchase of common stock | 4,029 | 2,127 | 2,127 | 2,150 |
| Proceeds from short-term debt, net | 10,673 | 9,349 | 8,784 | 11,984 |
| Repayment of short-term debt, net | 10,524 | 5,058 | 2,120 | 8,354 |
| Proceeds from long-term debt, net of issuance costs | 9,138 | 9,138 | 9,138 | 6,660 |
| Repayment of long-term debt | 1,755 | 754 | 751 | 804 |
| Proceeds from the exercise of stock options/employee withholding tax on stock awards, net | 1,831 | 557 | 450 | 714 |
| Credit support agreements activity, net | -246 | -271 | -3 | 5 |
| Settlement of convertible debt acquired from shockwave | 0 | 0 | - | 970 |
| Proceeds of short and long-term debt, net of issuance cost, related to the debt that transferred to kenvue at separation | - | - | - | 0 |
| Proceeds from kenvue initial public offering | - | - | - | 0 |
| Cash transferred to kenvue at separation | - | - | - | 0 |
| Other | -8 | 41 | 40 | -38 |
| Net cash used for financing activities | -4,170 | 4,757 | 10,422 | -1,792 |
| Effect of exchange rate changes on cash and cash equivalents | 178 | 224 | 70 | -91 |
| Decrease in cash and cash equivalents | -5,874 | -5,528 | 14,369 | -1,879 |
| Cash and cash equivalents at beginning of period | 24,105 | 24,105 | 24,105 | 21,859 |
| Cash and cash equivalents at end of period | 18,231 | 18,577 | 38,474 | 19,980 |
JOHNSON & JOHNSON (JNJ)
JOHNSON & JOHNSON (JNJ)